Superworth

Vertex Pharmaceuticals price to book ratio VRTX

Market value divided by the book value of the company's net assets, since 2010.

Today, Oct 23, 2026
6.6×
10-year median
7.2×
Against its 10-year history
39th
percentile: 0 is its lowest day, 100 its highest
10-year range
4.9× to 27.1×
Peer median
6.1×

Vertex Pharmaceuticals' price to book ratio is 6.6× as of Oct 23, 2026.

That is below its ten-year median of 7.2×, close to the middle of its last ten years.

Over that time it ranged from 4.9× in Nov 2021 to 27.1× in Jul 2017.

The median for 8 biotech stocks of a similar size is 6.1×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far6.6×5.6×7.2×
20256.8×5.5×7.9×
20246.7×5.8×8.7×
20236.3×5.3×6.5×
20225.7×5.7×7.3×
20215.9×4.9×7.6×
20207.6×6.9×11.8×
201910.8×8.5×17.1×
201814.2×13.8×23.9×
201721.2×18.5×27.1×
201617.9×17.9×29.5×
201533.5×22.6×37.7×
201424.6×11.0×24.7×
201313.6×9.6×26.3×
20128.6×8.2×14.7×
201111.9×9.6×34.3×
201010.9×6.6×12.0×

Against its peers

Companies in Biotechnology nearest Vertex Pharmaceuticals' size, closest first, today.

CompanyPrice to book ratio
VRTXVertex Pharmaceuticals6.6×
REGNRegeneron Pharmaceuticals2.6×
ONCBeOne Medicines8.3×
ALNYAlnylam Pharmaceuticals22.1×
UTHRUnited Therapeutics3.9×
INCYIncyte3.7×
EXELExelixis8.7×
NBIXNeurocrine Biosciences3.9×
HALOHalozyme Therapeutics99.3×
Peer median6.1×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Vertex Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.